Overview

Single Radiolabeled Dose Study to Investigate the Absorption, Metabolism and Excretion of [14C]-ETC-1002

Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
This Phase 1 study will assess the mass balance recover of carbon-14 (14C) labelled ETC-1002 and the routes and rates of excretion of [14C]-ETC-1002
Phase:
Phase 1
Details
Lead Sponsor:
Esperion Therapeutics
Esperion Therapeutics, Inc.
Treatments:
8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid